SIRPA and neoplasm: We established a MC38 tumor model, which is characterized by an abundance of intra-tumoral macrophages, to assess the antitumor potential of SMC18, a small molecule inhibitor targeting both CD47/SIRPα and PD-1/PD-L1 interactions.